NCT00976690View on ClinicalTrials.gov

Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

October 31, 2010

Study Completion Date

December 31, 2010

Conditions
Crohn Disease
Interventions
DRUG

Azathioprine OR Mesalazine

Azathioprine : 2mg/kg/day Mesalazine : 4g/day

Trial Locations (14)

14033

CHU CAEN, Caen

25030

Chu Besancon, Besançon

31403

Chu Toulouse, Toulouse

33604

Hopital Haut Leveque, Pessac

35033

Chu Rennes, Rennes

37044

Chu Tours, Tours

51000

Chu Reims, Reims

59037

Chru Lille, Lille

75010

Hopital Lariboisiere, Paris

Hopital Saint Louis, Paris

75012

Hopital St Antoine, Paris

75014

Hopital Cochin, Paris

80054

Chu Amiens, Amiens

92110

Hopital Beaujon, Clichy

All Listed Sponsors
lead

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER

NCT00976690 - Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease | Biotech Hunter | Biotech Hunter